Advertisement

Kidney Cancer pp 213-226 | Cite as

Allogeneic Hematopoetic Stem Cell Transplantation for Cytokine Refractory Renal Cell Carcinoma

  • Darrel Drachenberg
  • Richard W. CHilds
Part of the Cancer Treatment and Research book series (CTAR, volume 116)

Abstract

The treatment options for patients who develop metastatic renal cell carcinoma (RCC) are few. Conventional chemotherapeutics and radiotherapy rarely result in clinically beneficial responses. Fortunately, the past two decades has seen the development of promising immunotherapeutic approaches to treat metastatic RCC including the use of cytokines such as interleukin-2 and interferon-a, the adoptive infusion of lymphokine activated killer cells and tumor-infiltrating lymphocytes (TIL), and recently the development of dendritic cell based vaccination strategies. The promising results from these studies have forged the path for ongoing immunologically-based investigational approaches. Reduced intensity or nonmyeloablative allogeneic stem cell transplantation (NST) has recently been shown to produce potent immune-mediated anti-tumor responses in a variety of chemotherapy refractory hematologic malignancies while being associated with less morbidity and mortality compared to conventional “high dose” myeloablative regimens. Knowledge of RCC’s proclivity to be regulated by the immune system recently led investigators to test this type of transplant strategy in this malignancy. Pilot trials were based on the hypothesis that graft versus tumor (GVT) effects, analogous to the graft-vs-leukemia (GVL) effect seen in hematological malignancies, might be generated against an immuno-sensitive solid tumor following the transplantation of allogeneic donor T lymphocytes. The recent observation of regression of metastatic RCC following NST has confirmed the susceptibility of RCC to a GVT effect. Disease responses have been seen in patients who have failed traditional cytokine regimens and have occasionally included complete responses. Here we review the development and outcome of pilot immunotherapy trials based on the use of an allogeneic immune system.

Keywords

Human Leukocyte Antigen Conditioning Regimen Acute GVHD Donor Lymphocyte Infusion Human Renal Cell Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Reference

  1. 1.
    Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics CA. Cancer J Clin 1999, 49:8–31.CrossRefGoogle Scholar
  2. 2.
    Chow WH, Devesa SS, Warren JL, Fraumeni JFJ. Rising incidence of renal cell cancer in the United States. JAMA 1999, 281:1628–1631.PubMedCrossRefGoogle Scholar
  3. 3.
    Motzer RJ, Bander NH, Nanus DM. Renal cell carcinoma. NEJM 1996, 335:856.CrossRefGoogle Scholar
  4. 4.
    Lokich J, Harrison, JH. Renal cell carcinoma: natural history and chemotherapeutic experience. J Urol 1975:114–371.Google Scholar
  5. 5.
    Linehan WM, Shipley WU, Parkinson DR. Cancer of the kidney and ureter. In Devita VT Jr., ed. Cancer:Principles and practice of oncology4thedition. Philadelphia: JB Lippincott, 1993.Google Scholar
  6. 6.
    Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 1993, 20:303–314.Google Scholar
  7. 7.
    Bloom HJG. Medroxyprogesterone acetate (Provera) in the treatment of metastatic renal cell cancer. Br J Cancer 1971, 25:250.PubMedCrossRefGoogle Scholar
  8. 8.
    Smith EM, Kursh ED, Makley J, Resnick MI. Treatment of osseous metastasis secondary to renal cell carcinoma. j Urol 1992, 148:784.PubMedGoogle Scholar
  9. 9.
    Bumpus HC. The apparent disappearance of pulmonary metastasis in a case of hypernephroma following nephrectomy. J Urol 1928, 20:185.Google Scholar
  10. 10.
    Fairlamb DJ. Spontaneous regression of metastatic renal cell cancer. Cancer 1981, 47:2102.Google Scholar
  11. 11.
    Evanson TC, Cole WH. Spontaneous regression of cancer. WB Saunders, Philadelphia, 1996, 11–87.Google Scholar
  12. 12.
    Bloom HJG. Renal Cancer. InEndocrine therapy of Malignant disease.WBSaunders, Philadelphia, 1972, 339–367.Google Scholar
  13. 13.
    Gleave ME, Elhilali M, Fredet Y, et al. Interferon Gamma-1 b compared with placebo in metastatic renal cell carcinoma. NEJM 1998, 338:1265.PubMedCrossRefGoogle Scholar
  14. 14.
    Finke JH, Rayman P, Hart L, et al. Characterization of TIL subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, INF-y secretion and proliferation. J Immunother 1994, 15:91.CrossRefGoogle Scholar
  15. 15.
    Gaugler B, Brownvenstijn N, Vantomme V, et al. A new gene coding for an antigen recognized by autologous cytolytic T-Lymphocytes on human renal cell carcinoma. Immunogenetics 1996, 44: 323.PubMedCrossRefGoogle Scholar
  16. 16.
    Finke JH, Zea AH, Stanley J, et al. Loss of T-cell receptor Zeta chain and p561ck in T-cells infiltrating human renal cell carcinoma. Cancer Res 1993, 53:5613.PubMedGoogle Scholar
  17. 17.
    Li X, Liu J, Park JK, et al. T cells from renal cell carcinoma patients exhibit an abnormal pattern of Kappa B-specific DNA binding activity: a preliminary report. Cancer Res 1994, 54:5424.PubMedGoogle Scholar
  18. 18.
    Uzzo RG, Rayman P, Bloom T. Mechanisms of apoptosis in T-cells from patients with renal cell carcinoma. Clin Cancer Res 1999, 5:1219–1229.PubMedGoogle Scholar
  19. 19.
    Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma: the role of Interleukin-2. Cancer 1997, 80:1198–1220.PubMedCrossRefGoogle Scholar
  20. 20.
    Kugler A, Stuhler G, Walden P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000, 6:332–336.PubMedCrossRefGoogle Scholar
  21. 21.
    Horowitz M, Gale RP, Sondel P, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1991, 78:2120–2130.PubMedGoogle Scholar
  22. 22.
    Kolb HJ, Mittermueller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990, 76:2462–2465.PubMedGoogle Scholar
  23. 23.
    van Besien KW, de Lima M, Giralt SA, et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant 1997, 19:977–982.PubMedCrossRefGoogle Scholar
  24. 24.
    Verdonck L, Lokhorst H, Dekker A, et al. Graft-versus-myeloma effect in 2 cases. Lancet 1996, 347: 800–801.PubMedCrossRefGoogle Scholar
  25. 25.
    Eibl B, Schwaighofer H, Nachbaur D, et al. Evidence of a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996, 88:1501–1508.PubMedGoogle Scholar
  26. 26.
    Ueno NT, Rondon G, Mirza NQ, et al. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 1998, 16:986–993.PubMedGoogle Scholar
  27. 27.
    Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997, 89:4531–4536.PubMedGoogle Scholar
  28. 28.
    Slavin S, Nagler A, Naparastak E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non malignant hematologic diseases. Blood 1998, 91:756–763.PubMedGoogle Scholar
  29. 29.
    Khouri J, Keating MJ, Korbling M, et al. Transplant lite: induction of graft vs malignancy using fludarabine based nonablative chemotherapy and allogeneic progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998, 16:2817–2824.PubMedGoogle Scholar
  30. 30.
    Sykes M, Preffer F, McAfee S, et al. Mixed lymphohaemopoietic chimerism and graft-versuslymphoma effects after non-myeloablative therapy and HLA mismatched bone-marrow transplantation. Lancet 1999,353:1755–1759.PubMedCrossRefGoogle Scholar
  31. 31.
    Childs R, Clave E, Contentin N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism preceded alloimmune responses. Blood 1999, 94:3234–3241.PubMedGoogle Scholar
  32. 32.
    Sandmaier BM, McSweeney P,Yu C, Storb R. Nonmyeloablative transplants: preclinical and clinical results. Semin Oncol 2000, 27(suppl 5):78–81.PubMedGoogle Scholar
  33. 33.
    Bornhauser M, Thiede C, Schuler U, et al. Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin. Bone Marrow Transplant 2000, 26:119–125.PubMedCrossRefGoogle Scholar
  34. 34.
    Finke JH, Zea AH, Stanley J, et al. Loss of T-cell receptor zeta chain and p561ck in T-cells infiltrating human renal cell carcinoma. Cancer Res 1993,53:5613–5616.PubMedGoogle Scholar
  35. 35.
    Li X, Liu J, Park JK, et al. T cells from renal cell carcinoma patients exhibit an abnormal pattern of kappa B-specific DNA binding activity: a preliminary report. Cancer Res 1994,54:5424–5429.PubMedGoogle Scholar
  36. 36.
    Uzzo RG, Rayman P, Bloom T. Mechanisms of apoptosis in T-cells from patients with renal cell carcinoma. Clin Cancer Res 1999,5:1219–1229.PubMedGoogle Scholar
  37. 37.
    Childs R, Clave E, Tisdale J, et al. Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral blood progenitor cell transplant: evidence for a graft-versustumor effect. J Clin Oncol 1999,17:2044–2051.PubMedGoogle Scholar
  38. 38.
    Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000, 343: 750–758.PubMedCrossRefGoogle Scholar
  39. 39.
    Rini B, Zimmerman TM, Stadler W, et al. Allogeneic stem-cell transplantation of Renal Cell Cancer after nonmyeloablative chemotherapy: Feasibility, engraftment, and clinical results. J Clin Onc 2002, 20(8):2017–2024.CrossRefGoogle Scholar
  40. 40.
    Bregni M, Dodero A, Peccatori J, et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 2002, 99(11):4234–4236.PubMedCrossRefGoogle Scholar
  41. 41.
    Makimoto A, Mineishi S, Tanosaki R, et al. Nonmyeloablative stem cell transplantation (NST) for refractory solid tumors [abstract]. Proc Am Soc Clin Oncol 2001, 20:44.Google Scholar
  42. 42.
    Pedrazzoli P, Da Prada G, Giorgiani G, et al. Allogeneic blood stem cell transplantation after reduced intensity, preparative regimen–a pilot study in patients with refractory malignancies. Cancer 2002, 94(9):2409–2416.PubMedCrossRefGoogle Scholar
  43. 43.
    Flanigan RC, Salmon SE, Blummenstein EA, et al. Nephrectomy followed by interferon alpha-2b compared with interferon alpha-2b alone for metastatic renal cancer. NEJM 2001, 345:1655–1659.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2003

Authors and Affiliations

  • Darrel Drachenberg
  • Richard W. CHilds

There are no affiliations available

Personalised recommendations